```html

Yellowish Plaques on Skin (Xanthomas)

What is Yellowish plaques on skin (xanthomas)?

Xanthomas are firm, yellow‑to‑orange plaques or nodules that appear on the skin, tendons, or around the eyes. They are composed of lipid‑laden macrophages (foam cells) that collect in the dermis when blood‑lipid levels are high or when certain metabolic disorders alter lipid handling. Although they are not painful, xanthomas can be cosmetically concerning and, more importantly, may signal an underlying systemic disease that requires treatment.

Most people first notice them as smooth, slightly raised patches that are yellow‑golden in colour, often on the elbows, knees, hands, feet, buttocks, or eyelids. The lesions can vary in size from a few millimetres to several centimetres and may appear singly or in clusters.

Common Causes

The presence of xanthomas is a clue that something is off with the body’s lipid metabolism. Below are the most frequent conditions associated with yellowish plaques:

• Familial Hypercholesterolemia (FH) – an inherited disorder causing very high LDL‑cholesterol levels.
• Familial Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) – elevated remnants of VLDL/IDL leading to broad, flat xanthomas (palmar or tuberous).
• Type II (Familial) Hyperlipoproteinemia – high LDL with tendinous xanthomas on Achilles or extensor tendons.
• Type IV Hyperlipoproteinemia – increased VLDL, often producing eruptive xanthomas on the trunk.
• Type V Hyperlipoproteinemia – mixed elevation of triglycerides and cholesterol, can cause eruptive and tuberous xanthomas.
• Diabetes mellitus (especially poorly controlled) – may lead to eruptive xanthomas due to very high triglycerides.
• Primary biliary cholangitis & other cholestatic liver diseases – cause xanthelasma around the eyes.
• Lipoprotein Lipase Deficiency (Familial Chylomicronemia) – extremely high triglycerides with eruptive xanthomas.
• Secondary causes such as hypothyroidism, nephrotic syndrome, or medications (e.g., protease inhibitors, certain immunosuppressants).
• Rare systemic diseases – such as Erdheim‑Chester disease, Langerhans cell histiocytosis, or certain malignancies that can produce xanthoma‑like lesions.

Associated Symptoms

While xanthomas themselves are usually asymptomatic, they often appear alongside other clinical clues that point to the underlying disorder:

• Fatigue, weakness, or shortness of breath – may suggest cardiovascular disease from high cholesterol.
• Chest pain or angina – a sign of coronary artery disease, especially in FH.
• Abdominal pain or pancreatitis – can occur when triglycerides are >1000 mg/dL (common with eruptive xanthomas).
• Yellowing of the eyes (jaundice) or dark urine – clues to liver or biliary disease.
• Edema, especially facial or peripheral – may indicate nephrotic syndrome.
• Weight loss, polyuria, polydipsia – typical of uncontrolled diabetes.
• Joint pain or tendon thickening – seen with tendinous xanthomas.
• Family history of early heart attacks, strokes, or high cholesterol.

When to See a Doctor

Because xanthomas can be the first visible sign of a potentially serious metabolic disorder, you should schedule a medical evaluation if you notice any of the following:

• Newly appearing yellow plaques, especially if they are increasing in size or number.
• Any personal or family history of high cholesterol, early heart disease, or pancreatitis.
• Associated symptoms listed above (e.g., chest pain, abdominal pain, unexplained weight loss).
• Rapidly spreading eruptive xanthomas – these can herald a triglyceride level that puts you at risk for pancreatitis.
• Lesions around the eyes (xanthelasma) that appear before age 30.

Early medical attention helps identify the root cause and prevents long‑term complications.

Diagnosis

Diagnosing xanthomas involves both visual assessment and laboratory testing to uncover the underlying lipid abnormality.

Clinical Examination

• Physical inspection: location, size, pattern (tuberous, eruptive, tendinous, planar).
• Palpation: xanthomas are usually firm but not tender.
• Assessment for tendon thickening or other skin lesions.

Laboratory Tests

• Lipid panel – total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Apolipoprotein B & E typing – helps differentiate familial dyslipidemias.
• Fasting glucose & HbA1c – screen for diabetes.
• Liver function tests & bilirubin – evaluate cholestatic disease.
• Thyroid‑stimulating hormone (TSH) – rule out hypothyroidism.
• Urinalysis – look for proteinuria (nephrotic syndrome).

Imaging & Specialized Tests

• Ultrasound or CT of the abdomen to assess for fatty liver or pancreatic inflammation.
• Genetic testing for FH (LDLR, APOB, PCSK9 mutations) when a hereditary pattern is suspected.
• Skin biopsy (rarely needed) – confirms foam cells in the dermis.

Treatment Options

Treatment is two‑pronged: managing the underlying lipid disorder and, when desired, removing or reducing the skin lesions.

Medical Management

• Statins (e.g., atorvastatin, rosuvastatin) – first‑line for lowering LDL‑C.
• Ezetimibe – blocks intestinal cholesterol absorption; often added to statins.
• PCSK9 inhibitors (alirocumab, evolocumab) – especially effective in FH.
• Fibrates (gemfibrozil, fenofibrate) – reduce triglycerides; useful for eruptive xanthomas.
• Omega‑3 fatty acid ethyl esters – lower very high triglycerides.
• Bile‑acid sequestrants (cholestyramine) – can lower LDL when statins intolerant.
• Niacin – less commonly used due to side‑effects but can raise HDL‑C.
• Glucose‑lowering therapies for diabetic patients (metformin, GLP‑1 agonists) – improve lipid profile indirectly.

Goal‑directed therapy is based on the specific lipid abnormality and cardiovascular risk, as recommended by the American College of Cardiology/AHA guidelines.<sup>1</sup>

Lesion‑Focused Therapies

• Topical or intralesional steroids – sometimes reduce inflammatory component of eruptive lesions.
• Laser therapy (e.g., pulsed dye laser, CO₂ laser) – effective for cosmetic removal of planar or tuberous xanthomas.
• Surgical excision – reserved for large, solitary lesions that cause functional issues.
• Chemical cautery (trichloroacetic acid) – an outpatient option for smaller plaques.

Lesion‑directed treatments are usually pursued after the lipid abnormality is under control; otherwise, new plaques may continue to appear.

Lifestyle Measures

• Adopt a heart‑healthy diet: high in fiber, low in saturated/trans fats, and limited simple sugars.
• Increase omega‑3 intake (fatty fish, flaxseed, walnuts).
• Maintain a healthy weight – weight loss can lower triglycerides by 10‑20 %.
• Regular aerobic exercise (≥150 min/week) improves HDL‑C and lowers LDL‑C.
• Avoid tobacco and limit alcohol (especially important if triglycerides are high).

Prevention Tips

While you cannot always prevent genetic lipid disorders, you can reduce the risk of xanthoma formation through the following actions:

• Screen family members early if a hereditary dyslipidemia is known.
• Undergo routine lipid panels beginning at age 20 (or earlier with a strong family history).
• Follow physician‑prescribed lipid‑lowering medication consistently.
• Adopt the Mediterranean‑style diet – proven to lower LDL‑C and triglycerides.
• Stay active and keep a healthy waist circumference.
• Control diabetes, hypothyroidism, and other endocrine disorders promptly.
• Limit medications known to raise lipids; discuss alternatives with your clinician.

Emergency Warning Signs

References

1. American College of Cardiology/American Heart Association. 2023 Guideline on the Management of Blood Cholesterol. Circulation. 2023;148:e1‑e99.
2. Mayo Clinic. Xanthomas: Causes, Symptoms, and Treatment. https://www.mayoclinic.org. Accessed June 2026.
3. National Institutes of Health – National Lipid Association. Clinical Practice Guidelines for the Management of Dyslipidemia. 2022.
4. Cleveland Clinic. Familial Hypercholesterolemia: What You Need to Know. https://my.clevelandclinic.org. Accessed June 2026.
5. World Health Organization. WHO Guideline on the Management of Dyslipidaemias. 2021.
6. CDC. Diabetes and Lipid Management. https://www.cdc.gov. Accessed June 2026.

```